The prevalence of ocular surface complaints in Brazilian patients with glaucoma or ocular hypertension.
OBJECTIVE
To examine the prevalence of ocular surface complaints in Brazilian patients with glaucoma or ocular hypertension who used topical intraocular pressure (IOP)-lowering regimens.


METHODS
In this multicenter, noninterventional, single-visit study, adults with glaucoma or ocular hypertension treated with an IOP-lowering regimen were administered the 12-item ocular surface disease index (OSDI) questionnaire. Each response was scored on a 5-point scale, with 0 indicating symptom present none of the time and 4 indicating symptom present all of the time. The average of the 12 item responses for each patient was transformed to a scale from 0 to 100, with higher scores representing worse disabilities. OSDI results then were categorized as absence of OSD (scores of 0-12), mild OSD (scores of 13-22), moderate OSD (scores of 23-32), or severe OSD (scores of 33100).


RESULTS
The 173 enrolled patients had a mean age of 61.2 years, were women in 65.3% of cases, and had glaucoma in 89.0% of cases and ocular hypertension in 11.0% of cases. OSDI scores for 158 patients using 1 IOP-lowering therapy indicated no OSD in 37.3% of patients (59/158), mild OSD in 20.9% (33/158), moderate OSD in 17.1% (27/158), and severe OSD in 24.7% (39/158). For the 120 patients using 1 IOP-lowering medication and having a known duration of diagnosis of glaucoma or ocular hypertension, mean OSDI scores were numerically higher (worse) for the 39 patients with a diagnosis ≥6 years long (score 25 [± 20], indicating moderate OSD) than for the 81 patients with a diagnosis lasting <6 years (score 22 [± 20], indicating mild OSD); however, no significant differences in OSDI scores by duration of diagnosis were evident in means (P=0.49), distributions (P≥0.26), or correlation (P=0.77).


CONCLUSIONS
A large proportion of Brazilian patients treated with 1 IOP-lowering therapy had some ocular surface complaints.
Vital Paulino
VP
Costa
Italo Mundialino
IM
Marcon
Roberto Pedrosa
RP
Galvão Filho
Roberto Freire Santiago
RF
Malta
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001548:Benzalkonium Compounds / Q000627:therapeutic use; D001938:Brazil / Q000453:epidemiology; D003316:Corneal Diseases / Q000139:chemically induced / Q000453:epidemiology*; D015352:Dry Eye Syndromes / Q000453:epidemiology*; D005260:Female; D005901:Glaucoma / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000150:complications* / Q000188:drug therapy; D011310:Preservatives, Pharmaceutical / Q000627:therapeutic use; D015995:Prevalence; D011788:Quality of Life; D012016:Reference Values; D011795:Surveys and Questionnaires; D055815:Young Adult
D001548:Benzalkonium Compounds; D011310:Preservatives, Pharmaceutical